Get the app
Help
Download the app
Anghami Plus
Browse content
Moods and genres
Podcasts
OSN Plus
The ECTRIMS Podcast
by The European Committee for Treatment and Research in Multiple Sclerosis
57 EPISODES
Jun 12
Play for free
All Episodes
Biomarkers in MS
The European Committee for Treatment and Research in Multiple Sclerosis
BTK Inhibitors: The Tolebrutinib Trial Results
The European Committee for Treatment and Research in Multiple Sclerosis
The Role of Diet in Managing MS
The European Committee for Treatment and Research in Multiple Sclerosis
Autologous Haematopoietic Stem Cell Transplantation for MS
The European Committee for Treatment and Research in Multiple Sclerosis
How Real-World Data Is Shaping MS Treatment
The European Committee for Treatment and Research in Multiple Sclerosis
Fatigue in Multiple Sclerosis
The European Committee for Treatment and Research in Multiple Sclerosis
Advancing MS Knowledge through the ECTRIMS Fellowship
The European Committee for Treatment and Research in Multiple Sclerosis
Advancing MS Knowledge through the ECTRIMS Fellowship
The European Committee for Treatment and Research in Multiple Sclerosis
Addressing Diversity in MS Research and Care
The European Committee for Treatment and Research in Multiple Sclerosis
Paediatric Multiple Sclerosis
The European Committee for Treatment and Research in Multiple Sclerosis
MS Prodrome: Implications and Future Research Directions
The European Committee for Treatment and Research in Multiple Sclerosis
Episode 37: Future MS Therapeutics
The European Committee for Treatment and Research in Multiple Sclerosis
MS Nurses at ECTRIMS 2024
The European Committee for Treatment and Research in Multiple Sclerosis
Patient Community Day Highlights of ECTRIMS 2024: Part II
The European Committee for Treatment and Research in Multiple Sclerosis
Patient Community Day Highlights of ECTRIMS 2024: Part I
The European Committee for Treatment and Research in Multiple Sclerosis
Day 3 Highlights of ECTRIMS 2024
The European Committee for Treatment and Research in Multiple Sclerosis
Day 2 Highlights of ECTRIMS 2024
The European Committee for Treatment and Research in Multiple Sclerosis
Day 1 Highlights of ECTRIMS 2024
The European Committee for Treatment and Research in Multiple Sclerosis
Pre-Day Highlights of ECTRIMS 2024
The European Committee for Treatment and Research in Multiple Sclerosis
Episode 35: NMOSD and MOGAD Part II
The European Committee for Treatment and Research in Multiple Sclerosis
Episode 35: NMOSD and MOGAD Part I
The European Committee for Treatment and Research in Multiple Sclerosis
ECTRIMS-EAN Vaccination Consensus Statement (eanCast)
The European Committee for Treatment and Research in Multiple Sclerosis
Environmental, Genetic, and Epigenetic Risk Factors in MS
The European Committee for Treatment and Research in Multiple Sclerosis
Myelin plasticity and repair
The European Committee for Treatment and Research in Multiple Sclerosis
Lifestyle Modifications in MS
The European Committee for Treatment and Research in Multiple Sclerosis
The Impact of Ageing on MS
The European Committee for Treatment and Research in Multiple Sclerosis
Artificial Intelligence in MS Research
The European Committee for Treatment and Research in Multiple Sclerosis
Prioritising Women's Health Topics in MS Research
The European Committee for Treatment and Research in Multiple Sclerosis
Spotlight on Young MS Researchers
The European Committee for Treatment and Research in Multiple Sclerosis
MS in the Black Community
The European Committee for Treatment and Research in Multiple Sclerosis
Efforts Towards a Better MS Diagnostic Criteria
The European Committee for Treatment and Research in Multiple Sclerosis
Factoring in Female Health in the MS Journey
The European Committee for Treatment and Research in Multiple Sclerosis
The Importance of Patient Community Day
The European Committee for Treatment and Research in Multiple Sclerosis
Genetics and MS Severity
The European Committee for Treatment and Research in Multiple Sclerosis
Defining MS Subtypes in Clinical Practice
The European Committee for Treatment and Research in Multiple Sclerosis
The Changing Role of MS Nurses
The European Committee for Treatment and Research in Multiple Sclerosis
Discontinuing DMTs in Patients with Stable Relapsing-remitting MS: When and How?
The European Committee for Treatment and Research in Multiple Sclerosis
Day Three Highlights of MSMilan2023
The European Committee for Treatment and Research in Multiple Sclerosis
Day Two Highlights of MSMilan2023
The European Committee for Treatment and Research in Multiple Sclerosis
Day One Highlights of MSMilan2023
The European Committee for Treatment and Research in Multiple Sclerosis
Behind the landmark WHO decision on essential medicines for MS
The European Committee for Treatment and Research in Multiple Sclerosis
Women with MS
The European Committee for Treatment and Research in Multiple Sclerosis
Utilising Global Data Registries for MS Research
The European Committee for Treatment and Research in Multiple Sclerosis
Epstein-Barr Virus and Multiple Sclerosis
The European Committee for Treatment and Research in Multiple Sclerosis
Access For All: Adding MS DMTs to the WHO Essential Medicines List
The European Committee for Treatment and Research in Multiple Sclerosis
Using Real-World Studies to Compare DMTs in MS
The European Committee for Treatment and Research in Multiple Sclerosis
Remyelination in MS: a New Clinical Trial
The European Committee for Treatment and Research in Multiple Sclerosis
Stem Cell Research in Multiple Sclerosis
The European Committee for Treatment and Research in Multiple Sclerosis
ECTRIMS 2022 For People with MS: Part 3
The European Committee for Treatment and Research in Multiple Sclerosis
ECTRIMS 2022 For People with MS: Part 2
The European Committee for Treatment and Research in Multiple Sclerosis